|
|
|
|
Annex 1 has redefined expectations for sterile drug manufacturing, elevating contamination control and risk management from operational considerations to strategic imperatives. For sponsors, compliance is a critical lever for reducing risk, safeguarding value, and maintaining momentum from clinical development through commercialization.
|
|
|
|
|
Rapid analytical testing turnaround is essential to maintaining development timelines, meeting clinical milestones, and in commercial manufacturing, providing reliable drug supply to patients.
|
|
|
|
|
Strategic investment in infrastructure, equipment, and digital technologies enables reliable, flexible scaling of sterile injectable programs while maintaining quality, regulatory compliance, and operational efficiency.
|
|
|
|
|
Sponsors selecting CDMOs should prioritize collaborative partnerships, strong in‑house drug development capabilities, and U.S.-based operations to support efficient, compliant drug development programs.
|
|
|
|
|
In today’s fast-moving biopharma landscape, scaling from clinic to commercial takes more than expertise. See how collaboration can transform scale-up and drive confident progress
|
|
|
|
|
Discover how a people-first talent strategy, purpose-driven culture, and cross-functional collaboration come together to support scalable growth and operational excellence in commercial manufacturing.
|
|
|
|
|
|
|
A U.S.-based sterile injectable CDMO delivering scalable small and large molecule manufacturing, supported by advanced aseptic technologies, integrated quality systems, and commercial-ready capabilities.
|
|
|
|
|
|
|
Optima delivers high‑quality, flexible syringe and vial filling solutions with fast qualification, U.S.‑based support, and long‑term partnership reliability, helping CDMOs scale efficiently and confidently.
|
|
|
|
|
|
|
